Latest Caristo Diagnostics news, funding rounds and robotics & AI coverage. 1 article tracked by The Robotics Media.
Caristo Diagnostics is a UK-founded, dual-headquartered cardiovascular AI company that develops software for detecting and quantifying coronary inflammation from routine coronary CT angiography (CCTA). Its flagship CaRi-Heart platform generates a Fat Attenuation Index Score (FAI-Score) and 10-year cardiovascular mortality risk from standard CCTA scans. The company received FDA de novo authorization on July 29, 2026 for CaRi-Heart and previously secured FDA 510(k) clearance for its CaRi-Plaque plaque-analysis product in March 2025.